business strategy

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance

Pittsburgh, January 5, 2021 – Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that President and CEO Lisa Ricciardi is participating in the Biotech Showcase™ 2021 conference and providing an on-demand company presentation. In addition, Ms. Ricciardi will be participating in …

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance Read More »

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors

Pittsburgh, October 27, 2020 — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced the appointment of Brett P. Monia, Ph.D. to its board of directors. Dr. Monia is a founding member and the current CEO of Ionis Pharmaceuticals, a pioneer in …

Cognition Therapeutics Appoints Brett P. Monia to its Board of Directors Read More »

Cognition Therapeutics Announces Change in Leadership

New York, March 27, 2020 — Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Kenneth I. Moch has stepped down as president and chief executive officer to assume an advisory role. Lisa Ricciardi has transitioned from …

Cognition Therapeutics Announces Change in Leadership Read More »

Scroll to Top